Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOP1288 in symptomatic ulcerative colitis
NCT02888379Phase 2Completed
- Sponsor
- TopiVert Pharma Limited
- Start
- Sep 2016
- Primary completion
- Jun 2017
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in ulcerative colitis (UC) comparing TOP1288 with Placebo (2 arms). Primary endpoint: Mayo Clinic modified endoscopic subscore at 4 weeks. Started Sep 2016; status: completed.
02
Drugs
TOP-1288
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02888379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02888379.